Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death

Molecular and Cellular Biology

Volumn 28, Issue 2, 2008, Pages 529-538

  Knobloch, Jürgen ^a,b   Schmitz, Ingo ^a   Götz, Katrin ^a   Schulze Osthoff, Klaus ^a   Rüther, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CASPASE; FAS ANTIGEN; INSULIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN INHIBITOR; PROTEIN KINASE B; PTEN INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIRTH DEFECT; CELL DEATH; CHICKEN; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENE REPRESSION; INFLAMMATORY DISEASE; LIMB MALFORMATION; MICROPHTHALMIA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

EID: 37849052222     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00553-07     Document Type: Article

References (49)

1. Alessi, D. R., and P. Cohen. 1998. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8:55-62.
2. Andjelkovic, M., D. R. Alessi, R. Meier, A. Fernandez, N. J. Lamb, M. Frech, P. Cron, P. Cohen, J. M. Lucocq, and B. A. Hemmings. 1997. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272:31515-31524.
3. Banerjee, D., and A. Liefshitz. 2001. Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res. 21:3941-3947.
4. Beurel, E., and R. S. Jope. 2006. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol. 79:173-189.
5. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868.
6. Chauvier, D., S. Ankri, C. Charriaut-Marlangue, R. Casimir, and E. Jacotot. 2007. Broad-spectrum caspase inhibitors: from myth to reality? Cell Death Differ. 14:387-391.
7. Danial, N. N., and S. J. Korsmeyer. 2004. Cell death: critical control points. Cell 116:205-219.
8. Datta, S. R., A. Brunet, and M. E. Greenberg. 1999. Cellular survival: a play in three Akts. Genes Dev. 13:2905-2927.
9. Dealy, C. N., and R. A. Kosher. 1995. Studies on insulin-like growth factor-I and insulin in chick limb morphogenesis. Dev. Dyn. 202:67-79.
10. Dealy, C. N., and R. A. Kosher. 1996. IGF-I, insulin and FGFs induce outgrowth of the limb buds of amelic mutant chick embryos. Development 122:1323-1330.
11. Dearth, R. K., X. Cui, H. J. Kim, D. L. Hadsell, and A. V. Lee. 2007. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6:705-713.
12. Debock, C. A., and A. Peters. 1963. Effect of thalidomide on the development of the chick embryo. Nature 199:1204-1206.
13. Ding, V. W., R. H. Chen, and F. McCormick. 2000. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem. 275:32475-32481.
14. 632 in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 142:2833-2840.
15. Fukumoto, S., C. M. Hsieh, K. Maemura, M. D. Layne, S. F. Yet, K. H. Lee, T. Matusi, A. Rosenzweig, W. G. Taylor, J. S. Rubin, et al. 2001. Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 276:17479-17483.
16. Gockel, H. R., A. Lugering, J. Heidemann, M. Schmidt, W. Domschke, T. Kucharzik, and N. Lugering. 2004. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J. Immunol. 172:5103-5109.
17. Gordon, M. D., and R. Nusse. 2006. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281:22429-22433.
18. Hardt, S. E., and J. Sadoshima. 2002. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90:1055-1063.
19. Kim, D., and J. Chung. 2002. Akt: versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol. 35:106-115.
20. Knobloch, J., J. D. Shaughnessy, Jr., and U. Rüther. 2007. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J. 21:1410-1421.
21. Korinek, V., N. Barker, P. J. Morin, D. van Wichen, R. de Weger, K. W. Kinzler, B. Vogelstein, and H. Clevers. 1997. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784-1787.
22. Krueger, A., I. Schmitz, S. Baumann, P. H. Krammer, and S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276:20633-20640.
23. Leslie, N. R. 2006. The redox regulation of PI 3-kinase-dependent signaling. Antioxid. Redox Signal. 8:1765-1774.
24. Leslie, N. R., and C. P. Downes. 2004. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382:1-11.
25. Lim, S. J., Y. J. Lee, D. H. Park, E. Lee, M. K. Choi, W. Park, K. H. Chun, H. G. Choi, and J. S. Cho. 2007. Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis. Apoptosis 12:423-431.
26. Newman, L. M., E. M. Johnson, and R. E. Staples. 1993. Assessment of the effectiveness of animal developmental toxicity testing for human safety. Reprod. Toxicol. 7:359-390.
27. 2 release via mechanistically distinct processes. Br. J. Pharmacol. 130:1353-1361.
28. Niehrs, C. 2006. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469-7481.
29. Pan, L., J. Lu, X. Wang, L. Han, Y. Zhang, S. Han, and B. Huang. 2007. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 109:1676-1688.
30. Parman, T., M. J. Wiley, and P. G. Wells. 1999. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5:582-585.
31. Peter, M. E., and P. H. Krammer. 2003. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26-35.
32. Sawin, P. B., D. Crary, R. R. Fox, and H. M. Wuest. 1965. Thalidomide malformations and genetic background in the rabbit. Experientia 21:672-677.
33. Schmid, A. C., R. D. Byrne, R. Vilar, and R. Woscholski. 2004. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 566:35-38.
34. + double positive thymic lymphoma. Oncogene 25:7587-7596.
35. Simpson, L., J. Li, D. Liaw, I. Hennessy, J. Oliner, F. Christians, and R. Parsons. 2001. PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol. Cell. Biol. 21:3947-3958.
36. Smithells, R. W., and C. G. Newman. 1992. Recognition of thalidomide defects. J. Med. Genet. 29:716-723.
37. Stambolic, V., T. W. Mak, and J. R. Woodgett. 1999. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18:6094-6103.
38. Sugimori, K., K. Matsui, H. Motomura, T. Tokoro, J. Wang, S. Higa, T. Kimura, and I. Kitajima. 2005. BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-kappaB activation. J. Bone Miner. Metab. 23:411-419.
39. Tanaka, S., and J. R. Wands. 1996. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J. Clin. Investig. 98:2100-2108.
40. Taniguchi, C. M., B. Emanuelli, and C. R. Kahn. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7:85-96.
41. Taylor, J. M., P. J. Crack, J. A. Gould, U. Ali, P. J. Heitzog, and R. C. Iannello. 2004. Akt phosphorylation and NFkappaB activation are counter-regulated under conditions of oxidative stress. Exp. Cell Res. 300:463-475.
42. Thoma, B., M. Grell, K. Pfizenmaier, and P. Scheurich. 1990. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J. Exp. Med. 172:1019- 1023.
43. Tian, Q., X. C. He, L. Hood, and L. Li. 2005. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle 4:215-216.
44. Ui, M., T. Okada, K. Hazeki, and O. Hazeki. 1995. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem. Sci. 20:303-307.
45. Waite, K. A., and C. Eng. 2003. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum. Mol. Genet. 12:679-684.
46. Wang, X. 2001. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922-2933.
47. Wang, X., L. C. Trotman, T. Koppie, A. Alimonti, Z. Chen, Z. Gao, J. Wang, H. Erdjument-Bromage, P. Tempst, C. Cordon-Cardo, P. P. Pandolfi, and X. Jiang. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128:129-139.
48. 2/M. Mol. Cell. Biol. 19:8469-8478.
49. Zimmerman, L. B., J. M. de Jesus-Escobar, and R. M. Harland. 1996. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86:599-606.